Healthcare, Pharma & Life Sciences

Missoula – November 06, 2026 -- Inimmune's TLR7/8 agonist INI-4001 produced no dose-limiting toxicities in a 10-patient Phase 1 study of heavily pretreated advanced solid tumor patients, and the company is weighing a Phase 2a start as early as 2027, subject to funding or partnership support.

INI-4001 tolerated up to 7.2 μg/kg across five dose levels

The trial (NCT06302426) tested the investigational small molecule for safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary antitumor activity. Patients received INI-4001 intravenously once weekly across five escalating dose levels. Adverse events were primarily transient, consistent with innate immune activation, and generally resolved within 24 hours. No concerning pharmacokinetic findings were reported.

SAN DIEGO – November 06, 2026 -- The U.S. Food and Drug Administration granted Johnson & Johnson accelerated approval for RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj), a subcutaneous therapy co-formulated with Halozyme's ENHANZE technology, as a single agent for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), Halozyme Therapeutics (Nasdaq: HALO) announced.

FDA clears first dual-targeted therapy for post-chemotherapy, post-immunotherapy HNSCC

The indication covers adults whose disease has progressed on or after platinum-based chemotherapy and an anti-PD-(L)1 antibody. It excludes patients with HPV-associated oropharyngeal squamous cell carcinoma.

The approval is the first for a dual-targeted therapy in this setting. RYBREVANT FASPRO simultaneously targets epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition (MET), extending the product's dual-targeted profile beyond lung cancer.

New York – November 06, 2026 -- Inductive took first place in the OpenADMET CYP Direct Inhibition Blind Challenge, ranking ahead of more than 270 eligible participants. It is the company's fourth consecutive first-place finish in an OpenADMET competition.

NVIDIA finishes third and Recursion fourth in the CYP field

Participants predicted inhibition potency (pIC50) against four CYP isoforms (CYP3A4, CYP2D6, CYP2C9 and CYP1A2) for 750 compounds. The measurements for those compounds were withheld until the challenge closed. The field included teams from leading biopharma, academic and AI organizations.

CYP enzymes metabolize the majority of small molecule drugs. Compounds that inhibit them can cause dangerous drug-drug interactions, so drug hunters need to flag this liability early and steer designs away from it.

Delray Beach – November 06, 2026 -- The global high-performance liquid chromatography (HPLC) market is projected to grow from USD 7.86 billion in 2026 to USD 12.2 billion by 2031, a compound annual growth rate of 9.3%, according to MarketsandMarkets.

North America and pharma customers anchor 2025 demand

North America held the largest regional share in 2025 at 45%. Pharmaceutical and biopharmaceutical companies were also the largest end-user group at 45%. They use HPLC for drug development, purity assessment, release testing and stability monitoring.

Demand is also supported by impurity profiling, food analysis and environmental testing. Advances in UHPLC separation, automated method development and sensitive detection let laboratories handle complex samples and improve workflow efficiency.

Fullerton – November 06, 2026 -- Esperto Medical, Inc., a critical care and remote patient monitoring startup, has received a grant from the Translational Research Institute for Space Health (TRISH) to adapt its Resonance Sonomanometry (RSM) technology for microgravity and other extreme environments.

RSM measures arterial pressure with sound waves and needs no calibration

RSM uses sound waves at different frequencies to measure blood pressure directly within arteries. Esperto says this avoids the variability of other approaches. The system requires no calibration, which simplifies setup and use.

Platform targets three autonomous data streams for astronaut monitoring

Esperto's RSM technology is designed to assess the following autonomously:

SEOUL – November 06, 2026 -- VS Pharmtech reported complete remission in all seven patients in a Phase 1 trial of VS-101, a radiosensitizer for head and neck cancer, with no dose-limiting toxicities or serious adverse events. The U.S. Food and Drug Administration (FDA) has since approved the company's Phase 2 plans for head and neck cancer, breast cancer and glioblastoma.

VS-101 repurposes a 20-year-old drug at one-fifth of the original dose

VS-101 makes tumors more responsive to radiation. It weakens RAD51, a protein central to cancer cells' repair of radiation-induced DNA damage, which pushes the cells toward death. The drug has been in use for more than 20 years, and VS Pharmtech is developing it through drug repositioning. The company aims to give patients about 20% of the original dose. CEO Park Shin-young said the drug itself does not cause DNA damage or toxicity.

HANGZHOU – November 06, 2026 -- Zylox-Tonbridge Medical Technology (HKEX: 2190) and GL Capital will jointly invest about HK$1.482 billion in LifeTech Scientific (HKEX: 1302) for roughly 16.7% of its enlarged share capital. Zylox-Tonbridge also intends to pursue a potential merger with LifeTech.

Lighthouse Two vehicle becomes LifeTech's largest shareholder

The investment runs through GL Lighthouse Two Investment Limited, which will subscribe for newly issued LifeTech shares. On completion, Lighthouse Two becomes LifeTech's largest single shareholder. Zylox-Tonbridge holds 60% of the vehicle through an investment of about HK$889 million.

Both investors may acquire additional LifeTech shares to support closer collaboration.

Beverly Hills – November 06, 2026 -- Beverly Hills Body Academy (BHBA) has formed as the world's first body contouring academy permanently based in Beverly Hills, with a three-chair leadership team and membership restricted to board-certified and board-eligible plastic surgeons.

Three chairs lead the academy from a Wilshire Boulevard office

Dr. Alfredo Hoyos, pioneer of HD Liposuction, and Dr. Ashkan Ghavami, creator of the S-Curve, serve as Co-Chairmen. Dr. Kiya Movassaghi, past president of The Aesthetic Society, is Scientific Chair. The academy's office is at 9465 Wilshire Boulevard, Suite 300, in the Golden Triangle of Beverly Hills.

The chairs are joined by the BHBA Academy Council: Dr. Adam Rubinstein, Dr. Ali Tehrani, Dr. Al Aly, Dr. Jerry Chidester and Dr. Alexandre Sanfurgo. The Body Contouring Academy LLC operates the academy, and Ewan Mohammed is Founder and CEO.

Bad Neustadt an der Saale – November 06, 2026 -- RHÖN-KLINIKUM Campus Bad Neustadt has appointed Dr. Stefan Reisch (MHBA) as chief physician of its Department of Anesthesiology and Intensive Care Medicine, effective November 1, 2026. Reisch has worked at the site since 2009 and filled the role on an interim basis before the permanent appointment.

Reisch led the department on an interim basis in 2024 and again from July 1, 2026

Reisch served as senior attending physician and, most recently, as permanent deputy to the chief physician. He took over interim leadership under the department's collegial system in 2024 and resumed it on July 1, 2026.

Juliane Domke, managing director of the campus, said filling the post internally gives the clinic a leader who already knows the team and structures.

LOS ANGELES – November 06, 2026 -- LaserAway has opened its 241st location in Paramus, New Jersey, extending a 20-year expansion the company says included no clinic closures.

LaserAway runs 241 company-owned clinics in 36 states

Dr. Roy Winston and brothers Scott, Brock and Todd Heckmann founded the Los Angeles-based company in 2006 with a single clinic in West Hollywood. Every location is privately owned and operated, with no franchises. The Paramus opening coincides with the company's 20th anniversary this year.

Scott Heckmann, co-founder and CEO, said the company set out to make aesthetic treatments accessible to everyone, not only a privileged few.